Table TDI-8. Amphetamines, ecstasy and other non-cocaine stimulants: primary use among new and all clients entering treatment in 2006 for countries supplying data [see all tables in this series...]

Part (i) All clients with primary use of stimulants other than cocaine in treatment centres reported for the country

Country		Amphetamines	%	Ecstasy	%	Other stimulants	%	Total
Bulgaria		11	100.0	0	0.0	0	0.0	11
Czech Republic		4755	99.3	12	0.3	21	0.4	4788
Denmark		315	88.2	42	11.8	0	0.0	357
Ireland		30	24.4	93	75.6	0	0.0	123
Greece		2	7.1	8	28.6	18	64.3	28
Spain	(1)	384	57.5	228	34.1	56	8.4	668
France		89	29.0	203	66.1	15	4.9	307
Italy		65	23.1	198	70.5	18	6.4	281
Cyprus		0	0.0	15	100.0	0	0.0	15
Luxembourg		5	27.8	13	72.2	0	0.0	18
Hungary		681	51.1	347	26.1	304	22.8	1332
Malta		0	0.0	19	100.0	0	0.0	19
Netherlands		563	77.9	83	11.5	77	10.7	723
Austria		88	58.7	32	21.3	30	20.0	150
Romania		6	54.5	5	45.5	0	0.0	11
Slovenia	(2)	3	33.3	6	66.7	0	0.0	9
Slovakia		429	98.6	5	1.1	1	0.2	435
Finland		582	96.5	7	1.2	14	2.3	603
Sweden		2399	99.6	9	0.4	1	0.0	2409
United Kingdom	(3)	4134	83.3	739	14.9	89	1.8	4962
Turkey		1	0.9	107	99.1	0	0.0	108
Total		14542	83.8	2171	12.5	644	3.7	17357

Notes:

 All types of treatment centres as defined by TDI Protocol 2.0 are included. 

 Only countries supplying data were reported. 

 Percentage of drugs is percentage of all stimulants. 

 (1) Last data available refer to 2005. 

 (2) Last data available refer to 2004. It includes data for outpatient clients and clients treated in prison. Data for outpatient clients was validated, however data collection for prison clients was still in the process of development, thus figures are underestimated. With effect from next year the process of data validation for prison clients will be implemented.  

 (3) Data collection period refers to 1.4.2005 to 31.3.2006. 

 See also '‘General notes for interpreting data'’ on the Explanatory notes and help page. 

Sources:

 Reitox national reports 2007 — Standard table 3. 

• Download this data in Excel (.xls) format

(see the help page for information about formats etc.)